Landmark Trials in Lipid Reduction

Value in Health

Volumn 1, Issue 2, 1998, Pages 110-114

  Brown, W Virgil ^a  

^a ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013618353     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.120110.x     Document Type: Conference Paper

References (15)

1. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 \patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-23.
4. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
6. Glasziou PP, Simes RJ, Hall J. Design of a cost-effectiveness study within a randomized trial: the LIPID trial for secondary prevention of IHD. Long-term intervention with pravastatin in ischemic heart disease. Control Clin Trials 1997;18:464-76.
7. Lipid Research Clinics Investigators. The Lipid Research Clinics coronary primary prevention trial: results of 6-years of post trial follow-up. Arch Int Med 1992;152:1399-410.
8. Manninen V, Ello MO, Frick MM, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
9. Committee of Principal Investigators. A cooperative trial on primary prevention of the ischemic heart disease using clofibrate. Br Heart J 1978;10:1069-118.
10. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41.
11. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993;328(5):313-38.
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
13. Downs JR, Beere PA, Whitney E, et al. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS-TexCAPS). Am J Cardiol 1997;80:287-93.
14. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
15. McCormick LS, Black DM, Waters D, et al. Rationale, design and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT). Am J Cardiol 1997;80:1130-3.